HomeLatest ThreadsGreatest ThreadsForums & GroupsMy SubscriptionsMy Posts
DU Home » Latest Threads » Forums & Groups » Topics » Health » Deaf/Hard of Hearing (Group) » Frequency Therapeutics An...

Tue Apr 9, 2019, 08:32 PM

Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration

It's still early days, but this seems pretty interesting

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a clinical stage biotechnology company, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an investigational drug candidate designed to facilitate hearing restoration. The trial assessed the safety of a single dose of FX-322 given by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who had a medical history consistent with either chronic noise exposure or idiopathic sudden sensorineural hearing loss. In the Phase 1/2 study, FX-322 was safe and well tolerated following a single intratympanic injection with no serious adverse events. In addition, improvements in hearing function, including audiometry and word scores, were observed in multiple FX-322 treated patients.

Frequency is excited to announce positive results from our Phase 1/2 safety study of FX-322 in adults with sensorineural #hearingloss. All safety endpoints were met and signs of functional hearing improvement were observed in multiple patients.

Tweet this
“Hearing loss affects millions of people and current treatments are unable to restore hearing once it is lost,” said Susan Marenda King, M.D., a Neurotologist at the Ear Medical Group in San Antonio, TX and lead enroller in the clinical trial. “The study results for FX-322, which show signs of functional hearing improvement, are very promising and represent an exciting step toward a potential treatment for patients.”

“While the focus of this study was safety, we are excited to see initial results in sensorineural hearing restoration as there are currently no treatments to restore hearing for these patients,” said David L. Lucchino, President, Co-founder and CEO of Frequency. “Furthermore, this data provides support for our small-molecule-driven regenerative medicine platform, which has the opportunity to address numerous degenerative diseases.”

https://www.businesswire.com/news/home/20190409005363/en/Frequency-Therapeutics-Announces-Positive-Phase-12-Data

3 replies, 1114 views

Reply to this thread

Back to top Alert abuse

Always highlight: 10 newest replies | Replies posted after I mark a forum
Replies to this discussion thread
Arrow 3 replies Author Time Post
Reply Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration (Original post)
pscot Apr 2019 OP
LastDemocratInSC Apr 2019 #1
pscot Apr 2019 #2
area51 Apr 2019 #3

Response to pscot (Original post)

Tue Apr 9, 2019, 09:43 PM

1. What did you say?

Reply to this post

Back to top Alert abuse Link here Permalink


Response to LastDemocratInSC (Reply #1)

Wed Apr 10, 2019, 08:48 AM

2. It supposedly triggers regrowth

of the tiny hairlike thingys in our ears that enable hearing. Wonderful, if true.

Reply to this post

Back to top Alert abuse Link here Permalink


Response to pscot (Original post)

Tue Apr 16, 2019, 11:34 PM

3. k&r n/t

Reply to this post

Back to top Alert abuse Link here Permalink

Reply to this thread